Daplyza M 5/850 mg Tablet – Dual-Action Glucose Control
Daplyza M 5/850 mg Tablet – Dual-Action Glucose Control
Daplyza M 5/850 mg Tablet – Dual-Action Glucose Control
Description
Daplyza M 5/850 mg Tablet – Effective Combination for Type 2 Diabetes
Daplyza M is a fixed-dose tablet combining dapagliflozin (5 mg), an SGLT2 inhibitor, with metformin HCl (850 mg), a biguanide.
This dual therapy works in two complementary ways: dapagliflozin reduces blood sugar by increasing the removal of glucose through urine, while metformin lowers glucose production in the liver and improves the body’s response to insulin.
It’s used in patients with type 2 diabetes when metformin alone is not enough, thereby providing stronger glycemic control and reducing the risk of long-term complications.


